pharma-congress-molecular-medicine-2018-keynote

2 / 6

O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n
Note:
Page 13
Pharma Congress 2018 & Molecular Medicine 2018
& Psychiatric Disorders 2018 Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN: 2249-622X| Volume 8
International Conference on
PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS
19th International Conference on
CELLULAR AND MOLECULAR MEDICINE
19th Annual Congress on
PSYCHIATRY AND PSYCHIATRIC DISORDERS
&
&
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Archakov A I, Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C3-007
PHOSPHOLIPID MICELLES AS THE
MEDICINES THEMSELVES AND DRUG
DELIVERY SYSTEM
Phospholipids, especially phosphatidylcholine, are very commonly used in
medicine as a drug delivery system: most investigated of them are lipo-
somes. The aim of work was the use of phospholipid micelles rather liposomes
as drug delivery systems and as drugs themselves. To obtain the phospholipid
micelles are extremely small size we used homogenization under high pres-
sure, ultrafiltration and freeze-drying. Phosphogliv is Russian original drug,
which includes the phospholipid micelles with a size of 30-50 nm in diameter
with incorporated glycyrrhizinic acid, which possesses weak detergent proper-
ties and the ability to induce the synthesis of ƴ-interferon was used for the treat-
ment of liver diseases including viral hepatitis (B and C). Phosphogliv exists on
pharmaceutical Russian market with volume of ~ 2 bln. of dollars. Since 2016
the other phospholipids micelles with size of 15-25 nm in diameter without gly-
cyrrhizin acid were produced for improvement of reverse cholesterol transport
and normalization of lipid metabolism. Phospholipid micelles as drug delivery
system are biodegradable, biologically inert, do not cause allergic, antigenic, or
pyrogenic reaction. The new technology was created to produce phospholipid
micelles with such particle’s diameter in the form of lyophilic powder, which is
stable at storage. The main principles of incorporation of pharmacologically
active substances such as doxorubicine, arbidole, rifampicine etc. into phos-
pholipid micelles considerably increased their bioavailability and therapeutic
efficiency.
Biography
Archakov A I Scientific Advisor of Institute of Bio-
medical Chemistry, Was born January 10, 1940, in
Kashin, Kalinin (Tver) region – scientist, biochem-
ist.A.I. Archakov had organized a scientific school
to study molecular organization and functioning
of oxygenase cytochrome P450-containing sys-
tems, molecular mechanisms of the structure and
function of membranes and biological oxidation.
Under the guidance of A. I. Archakov, the institute’s
members have developed a fundamentally new
pharmaceutical composition “Phosphogliv” with
antiviral activity for the treatment of liver diseases
of various etiology. A.I. Archakov’s present-day/
current areas of expertise relate to research in the
field of post-genomic technologies, nanobiotech-
nologies, proteomics, development of approaches
to create personalized medicine of the future.A.I.
Archakov is the pioneer in the development of pro-
teomics in Russia.
Archakov A I
Institute of Biomedical Chemistry
Russian Federation